Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

Individuals can make various changes to their lifestyles to help reduce their chances of developing certain types of cancer, ...

A study shows that combining dual immunotherapy with chemotherapy improves outcomes for metastatic non-squamous NSCLC patients with STK11 and KEAP1 mutations. Learn more ...

"STK11 and KEAP1 alterations are common in patients with NSCLC and are linked to poor clinical outcomes with current standard-of-care first-line treatments," said co-lead author Ferdinandos ...

The trial entitled “Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway- Deficient NSCLC” is a Phase I/II trial where Phase I is a dose escalation study establishing the ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the ...

Study results, published today in Nature, identify KEAP1 and STK11 as potential biomarkers to stratify patients most likely to benefit from the addition of CTLA-4 immune checkpoint inhibitors ...

Study finds patients with advanced non-small cell lung cancer and STK11 and/or KEAP1 mutations had improved outcomes with combination treatment Study results, published today in Nature ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient ...